20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Down 45.5% in May

20/20 Biolabs Inc (NASDAQ:AIDX) saw a significant decrease in short interest in May. As of May 15th, there was short interest totaling 18,050 shares, a decrease of 45.5% from the April 30th total of 33,116 shares. Based on an average daily volume of 70,768 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the shares of the company are sold short.

20/20 Biolabs Price Performance

Shares of 20/20 Biolabs stock opened at $0.87 on Monday. The company has a fifty day moving average price of $1.57. 20/20 Biolabs has a fifty-two week low of $0.83 and a fifty-two week high of $50.00.

20/20 Biolabs (NASDAQ:AIDX) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.28) earnings per share for the quarter. The firm had revenue of $0.35 million during the quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on AIDX shares. Wall Street Zen raised 20/20 Biolabs to a “hold” rating in a research note on Saturday, March 14th. Maxim Group started coverage on 20/20 Biolabs in a research note on Monday, May 11th. They issued a “buy” rating and a $5.00 price target for the company. Finally, Weiss Ratings started coverage on 20/20 Biolabs in a research note on Thursday, May 14th. They issued a “sell (e-)” rating for the company. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.00.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.